Resistance to PD-1 blockade is frequently accompanied by the compensatory upregulation of alternative inhibitory receptors such as CTLA-4, TIGIT, TIM-3, or LAG-3, which sustain T cell dysfunction and maintain an immunosuppressive tumor milieu. This evidence concerns the gene PDCD1 and neoplasm.